Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD).

Saved in:
Bibliographic Details
Title: Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD).
Authors: Ng RA; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Barratt S; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Parisian A; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Palanisamy GS; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Phukan S; Aragen Life Sciences Private Ltd., Hyderabad 500076, India., Sun R; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Robello B; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Peña G; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Sapugay J; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Yeghikyan D; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Wang C; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Satish Kher S; Aragen Life Sciences Private Ltd., Hyderabad 500076, India., Thangathirupathy S; Aragen Life Sciences Private Ltd., Hyderabad 500076, India., Millikin R; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Yu G; Synterys, Inc., Union City 94587, California, United States., Watanabe T; Adesis, Inc., New Castle 19720, Delaware, United States., Zhou F; Adesis, Inc., New Castle 19720, Delaware, United States., Rich B; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Duncan A; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Andersen SE; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Chawla R; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Zak DR; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood 60153, Illinois, United States., Heerding DA; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Hearn BR; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Greene G; The Ben May Department for Cancer Research, University of Chicago, Chicago 60637, Illinois, United States., Harmon CL; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Hodges-Gallagher L; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Kushner PJ; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States., Fanning SW; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood 60153, Illinois, United States., Myles DC; Olema Oncology, 780 Brannan Street, San Francisco 94107, California, United States.
Source: ACS omega [ACS Omega] 2025 May 29; Vol. 10 (22), pp. 22685-22700. Date of Electronic Publication: 2025 May 29 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101691658 Publication Model: eCollection Cited Medium: Internet ISSN: 2470-1343 (Electronic) Linking ISSN: 24701343 NLM ISO Abbreviation: ACS Omega Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2470-1343
DOI:10.1021/acsomega.4c11023